BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia

British Journal of Haematology

Volumn 157, Issue 4, 2012, Pages 446-456

  Roy, Swagata ^a   Jørgensen, Heather G ^b   Roy, Poornima ^a   Abed El Baky, Mohamed ^a   Melo, Junia V ^c   Strathdee, Gordon ^d   Holyoake, Tessa L ^b   Bartholomew, Chris ^a  

^a GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

BCR ABL1; Chronic myeloid leukaemia; Imatinib; MECOM; Tyrosine kinase

Indexed keywords

BCR ABL1 PROTEIN; IMATINIB; MECOM PROTEIN; MESSENGER RNA; ONCOPROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BCR ABL1 GENE; CANCER CELL CULTURE; CANCER STEM CELL; CD34 SELECTION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COLONY FORMING CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; EMBRYO; ENZYME ACTIVITY; FEMALE; GENE ACTIVITY; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; MALE; MECOM GENE; MOLECULAR PATHOLOGY; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; CELL LINE; CELL PROLIFERATION; DNA-BINDING PROTEINS; ENZYME ACTIVATION; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; GENE EXPRESSION REGULATION, LEUKEMIC; GENE ORDER; GENE SILENCING; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENES; PYRIMIDINES; TRANSCRIPTION FACTORS;

EID: 84859944702     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09078.x     Document Type: Article

References (54)

1. Alzuherri, H., McGilvray, R., Kilbey, A. & Bartholomew, C. (2006) Conservation and expression of a novel alternatively spliced Evi1 exon. Gene, 384, 154-162.
2. Aytekin, M., Vinatzer, U., Musteanu, M., Raynaud, S. & Wieser, R. (2005) Regulation of the expression of the oncogene EVI1 through the use of alternative mRNA 5′-ends. Gene, 15, 160-168.
3. Barjesteh van Waalwijk van Doorn-Khosrovani, S., Erpelinck, C., van Putten, W.L., Valk, P.J., van der Poel-van de Luytgaarde, S., Hack, R., Slater, R., Smit, E.M., Beverloo, H.B., Verhoef, G., Verdonck, L.F., Ossenkoppele, G.J., Sonneveld, P., de Greef, G.E., Löwenberg, B. & Delwel, R. (2003) High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood, 101, 837-845.
4. Bartholomew, C., Kilbey, A., Clark, A.M. & Walker, M. (1997) The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation. Oncogene, 14, 569-577.
5. Ben-Neriah, Y., Daley, G.Q., Mes-Masson, A.M., Witte, O.N. & Baltimore, D. (1986) The chronic myelogenous leukaemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science, 85, 212-214.
6. Bianchini, M., Martinelli, G., Renzulli, M., Gonzalez Cid, M. & Larripa, I. (2007) cDNA microarray study to identify expression changes relevant for apoptosis in K562 cells co-treated with amifostine and imatinib. Cancer Chemotherapy and Pharmacology, 59, 349-360.
7. Carapeti, M., Goldman, J.M. & Cross, N.C. (1996) Overexpression of EVI-1 in blast crisis of chronic myeloid leukemia. Leukemia, 10, 1561.
8. Carlesso, N., Frank, D. & Griffin, J.D. (1996) Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. The Journal of Experimental Medicine, 183, 811-820.
9. Daghistani, M., Marin, D., Khorashad, J.S., Wang, L., May, P.C., Palliompeis, C., Milojkovic, D., De Melo, V.A., Gerrard, G., Goldman, J.M., Apperley, J.F., Clark, R.E., Foroni, L. & Reid, A.G. (2010) EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-gneration tyrosine kinase inhibitors. Blood, 116, 6014-6017.
10. De Weer, A., Poppe, B., Cauwelier, B., Carlier, A., Dierick, J., Verhasselt, B., Philippé, J., Van Roy, N. & Speleman, F. (2008) EVI1 activation in blast crisis CML due to juxtaposition to the rare 17q22 partner region as part of a 4-way variant translocation t(9;22). BMC Cancer, 8, 193.
11. Elrick, L.J., Jørgensen, H.G., Mountford, J.C. & Holyoake, T.L. (2005) Punish the parent not the progeny. Blood, 105(5), 1862-1866.
12. Fabbro, D., Buchdunger, E., Wood, J., Mestan, J., Hofmann, F., Ferrari, S., Mett, H., O'Reilly, T. & Meyer, T. (1999) Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacology and Therapeutics, 82, 293-301.
13. Fears, S., Mathieu, C., Zeleznik-Le, N., Huang, S., Rowley, J.D. & Nucifora, G. (1996) Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proceedings of the National Academy of Sciences of the United States of America, 93, 1642-1647.
14. Gerhardt, T.M., Schmahl, G.E., Flotho, C., Rath, A.V. & Niemeyer, C.M. (1997) Expression of the Evi-1 gene in haemopoietic cells of children with juvenile myelomonocytic leukaemia and normal donors. British Journal Haematology, 99, 882-887.
15. Goyama, S., Yamamoto, G., Shimabe, M., Sato, T., Ichikawa, M., Ogawa, S., Chiba, S. & Kurokawa, M. (2008) Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell, 3, 207-220.
16. Håkansson, P., Nilsson, B., Andersson, A., Lassen, C., Gullberg, U. & Fioretos, T. (2008) Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation. Genes Chromosomes Cancer, 47, 267-275.
17. Hamilton, A., Gallipoli, P., Nicholson, E. & Holyoake, T.L. (2010) Targeted therapy in haematological malignancies. Journal of Pathology, 220, 404-418.
18. Henzan, H., Yoshimoto, G., Okeda, A., Nagasaki, Y., Hirano, G., Takase, K., Tanimoto, T., Miyamoto, T., Fukuda, T., Nagafuji, K. & Harada, M. (2004) Myeloid/natural killer cell blast crisis representing an additional translocation, t(3;7)(q26;q21) in Philadelphia-positive chronic myelogenous leukemia. Annals of Hematology, 83, 784-788.
19. Hoyt, P.R., Bartholomew, C., Davis, A.J., Yutzey, K., Gamer, L.W., Potter, S.S., Ihle, J.N. & Mucenski, M.L. (1997) The Evi1 proto-oncogene is required at midgestation for neural, heart, and paraxial mesenchyme development. Mechanisms of Development, 65, 55-70.
20. Huang, S. (1999) The retinoblastoma protein-interacting zinc finger gene RIZ in 1p36-linked cancers. Frontiers in bioscience, 4, D528-D532.
21. Irvine, D.A., Heaney, N.B. & Holyoake, T.L. (2010) Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors-a synthesis of clinical and laboratory data. Blood Reviews, 24, 1-9.
22. Jørgensen, H.G., Allan, E.K., Graham, S.M., Godden, J.L., Richmond, L., Elliott, M.A., Mountford, J.C., Eaves, C.J. & Holyoake, T.L. (2005) Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia, 19, 1184-1191.
23. Khanna-Gupta, A., Lopingco, M.C., Savinelli, T., Zibello, T., Berliner, N. & Perkins, A.S. (1996) Retroviral insertional activation of the EVI1 oncogene does not prevent G-CSF-induced maturation of the murine pluripotent myeloid cell line 32Dcl3. Oncogene, 12, 563-569.
24. Kilbey, A. & Bartholomew, C. (1998) Evi-1 ZF1 DNA binding activity and a second distinct transcriptional repressor region are both required for optimal transformation of Rat1 fibroblasts. Oncogene, 16, 2287-2291.
25. Konopka, J.B., Watanabe, S.M. & Witte, O.N. (1984) An alteration of the human c-abl protein in K562 leukaemia cells unmasks associated tyrosine kinase activity. Cell, 37, 1035-1042.
26. Kurzrock, R., Gutterman, J.U. & Talpaz, M. (1988) The molecular genetics of Philadelphia chromosome positive leukaemias. New England Journal of Medicine, 319, 990-998.
27. Kustikova, O., Fehse, B., Modlich, U., Yang, M., Düllmann, J., Kamino, K., von Neuhoff, N., Schlegelberger, B., Li, Z. & Baum, C. (2005) Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science, 308, 1171-1174.
28. Lin, P., Lennon, P.A., Yin, C.C. & Abruzzo, L.V. (2009) Chronic myeloid leukemia in blast phase associated with t(3;8)(q26;q24). Cancer Genetics and Cytogenetics, 193, 119-122.
29. Livak, K.J. & Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-408.
30. Lugthart, S., van Drunen, E., van Norden, Y., van Hoven, A., Erpelinck, C.A., Valk, P.J., Beverloo, H.B., Löwenberg, B. & Delwel, R. (2008) High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 over expression and chromsome 3q26 abnormalities underestimated. Blood, 111, 4329-4337.
31. Lugthart, S., Figueroa, M.E., Bindels, E., Skrabanek, L., Valk, P.J.M., Li, Y., Meyer, S., Erpelinck-Verschueren, C., Greally, J., Löwenberg, B., Melnick, A. & Delwel, R. (2011) Aberrant DNA hypermethylation signature in acute myeloid leukaemia directed by EVI1. Blood, 117, 234-241.
32. Melo, J.V. & Barnes, D.J. (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nature Reviews Cancer, 7, 441-453.
33. Mitani, K., Ogawa, S., Tanaka, T., Miyoshi, H., Kurokawa, M., Mano, H., Yazaki, Y., Ohki, M. & Hirai, H. (1994) Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO Journal, 13, 504-510.
34. Morishita, K., Parker, D.S., Mucenski, M.L., Jenkins, N.A., Copeland, N.G. & Ihle, J.N. (1988) Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell, 54, 831-840.
35. Morishita, K., Parganas, E., Douglass, E.C. & Ihle, J.N. (1990a) Unique expression of the human Evi-1 gene in an endometrial carcinoma cell line: sequence of cDNAs and structure of alternatively spliced transcripts. Oncogene, 5, 963-971.
36. Morishita, K., Parganas, E., Bartholomew, C., Sacchi, N., Valentine, M.B., Raimondi, S.C., Le Beau, M.M. & Ihle, J.N. (1990b) The human Evi-1 gene is located on chromosome 3q24-q28 but is not rearranged in three cases of acute nonlymphocytic leukemias containing t(3;5)(q25;q34) translocations. Oncogene Research, 5, 221-231.
37. Morishita, K., Parganas, E., William, C.L., Whittaker, M.H., Drabkin, H., Oval, J., Taetle, R., Valentine, M.B. & Ihle, J.N. (1992) Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proceedings of the National Academy of Sciences of the United States of America, 89, 3937-3941.
38. Nakamura, Y., Nakazato, H., Sato, Y., Furusawa, S. & Mitani, K. (2002) Expression of the TEL/EVI1 fusion transcript in a patient with chronic myelogenous leukemia with t(3;12)(q26;p13). American Journal of Hematology, 69, 80-82.
39. Nunoda, K., Tauchi, T., Takaku, T., Okabe, S., Akahane, D., Sashida, G., Ohyashiki, J.H. & Ohyashiki, K. (2007) Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors. Oncogene, 26, 4179-4188.
40. Ogawa, S., Kurokawa, M., Tanaka, T., Tanaka, K., Hangaishi, A., Mitani, K., Kamada, N., Yazaki, Y. & Hirai, H. (1996) Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia. Leukemia, 10, 788-794.
41. O'Hare, T., Corbin, A.S. & Druker, B.J. (2006) Targeted CML therapy: controlling drug resistance, seeking cure. Current Opinion in Genetics and Development, 16, 92-99.
42. Paquette, R.L., Nicoll, J., Chalukya, M., Elashoff, D., Shah, N.P., Sawyers, C., Spiteri, E., Nanangud, G. & Rao, P.N. (2011) Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors. Cancer Genetics, 204, 392-397.
43. Pendergast, A.M., Quilliam, L.A., Cripe, L.D., Bassing, C.H., Dai, Z., Li, N., Batzer, A., Rabun, K.M., Der, C.J., Schlessinger, J. & Gishizky, M.L. (1993) BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell, 75, 175-185.
44. Russell, M., Thompson, F., Spier, C. & Taetle, R. (1993) Expression of the EVI1 gene in chronic myelogenous leukemia in blast crisis. Leukemia, 7, 1654-1657.
45. Sellers, S., Gomes, T.J., Larochelle, A., Lopez, R., Adler, R., Krouse, A., Donahue, R.E., Childs, R.W. & Dunbar, C.E. (2010) Ex vivo expansion of retrovirally transduced primate CD34(+) cells results in overrepresentation of clones with MDS1/EVI1 insertion sites in the myeloid lineage after transplantation. Molecular Therapy, 18, 1633-1639.
46. Skorski, T., Bellacosa, A., Nieborowska- Skorska, M.N., Majewski, M., Martinez, R., Choi, J.K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T.O., Wasik, M.A., Tsichlis, P.N. & Calabretta, B. (1997) Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO Journal, 16, 6151-6161.
47. Smith, D.L., Burthem, J. & Whetton, A.D. (2003) Molecular pathogenesis of chronic myeloid leukaemia. Expert Reviews in Molecular Medicine, 5, 1-27.
48. Stevens-Kroef, M., Poppe, B., van Zelderen-Bhola, S., van den Berg, E., van der Blij-Philipsen, M., Geurts van Kessel, A., Slater, R., Hamers, G., Michaux, L., Speleman, F. & Hagemeijer, A. (2004) Translocation t(2;3)(p15-23;q26-27) in myeloid malignancies: report of 21 new cases, clinical, cytogenetic and molecular genetic features. Leukemia, 18, 1108-1114.
49. Suzukawa, K., Taki, T., Abe, T., Asoh, H., Kamada, N., Yokota, J. & Morishita, K. (1997) Identification of translocational breakpoints within the intron region before the last coding exon (exon 12) of the EVI1 gene in two cases of CML-BC with inv(3)(q21q26). Genomics, 42, 356-360.
50. Valent, P. (2010) Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor? European Journal of Clinical Investigation, 40, 918-931.
51. Wetzler, M., Talpaz, M., Van Etten, R.A., Hirsch-Ginsberg, C., Beran, M. & Kuzrock, R. (1993) Subcellular localisation of Bcr, Abl and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. Journal of Clinical Investigation, 92, 1925-1939.
52. Wieser, R. (2007) The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene, 396, 346-357.
53. Wimmer, K., Vinatzer, U., Zwirn, P., Fonatsch, C. & Wieser, R. (1998) Comparative expression analysis of the antagonistic transcription factors EVI1 and MDS1-EVI1 in murine tissues and during in vitro hematopoietic differentiation. Biochemical and Biophysical Research Communications, 252, 691-696.
54. Yuasa, H., Oike, Y., Iwama, A., Nishikata, I., Sugiyama, D., Perkins, A., Mucenski, M.L., Suda, T. & Morishita, K. (2005) Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO Journal, 24, 1976-1987.